Molecular Targeting Technologies will supply Isotopia Molecular Imaging with no-carrier-added 177Lu to support development of its radiotherapeutic solutions
Molecular Targeting Technologies to supply n.c.a. 177Lu to Isotopia Molecular Imaging
March 29, 2021
by John R. Fischer, Senior Reporter
Molecular Targeting Technologies Inc. (MTTI), a biopharmaceutical company, will supply Isotopia Molecular Imaging with no-carrier-added 177Lu (n.c.a. 177Lu ).
The supply will support clinical development of MTTI's products, 177Lu-EBTATE, for targeting somatostatin receptors type 2 in a variety of neuroendocrine tumors (NETs); and 177Lu-EBRGD, for integrin expressing cancers in glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC).
"We've secured a timely and sustainable supply of a key therapeutic ingredient needed for the development and launch of our lead asset 177Lu-EBTATE and other EB platform technologies,” said Dr. Chris Pak, president and CEO of MTTI, in a statement.
177Lu is designed to precisely destroy tumors when bound to disease-specific, targeting therapeutics and can penetrate soft tissue at a maximum of one millimeter from its binding site. It is covered by the NIH's Evans Blue Platform technology patents. The EB helps boost 177Lu's half-life of 6.7 days and delivers a high dosage to the targeted tumor.
Isotopia uses a unique, stable GMP method to produce a highly pure form of 177Lu. n.c.a. and eliminates cost-intensive clinical waste management.
MTTI plans to sell it through an exclusive NIH worldwide license.
"Our strategy is to be a partner to every leading pharmaceutical company developing Lu-177 n.c.a.-based products, supporting them from clinical trials through commercial sale. We are committed to produce 52 weeks per year, ensuring supply through long-term contracts,” said Isotopia's CEO Dr. Eli Shalom.
The supply will support clinical development of MTTI's products, 177Lu-EBTATE, for targeting somatostatin receptors type 2 in a variety of neuroendocrine tumors (NETs); and 177Lu-EBRGD, for integrin expressing cancers in glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC).
"We've secured a timely and sustainable supply of a key therapeutic ingredient needed for the development and launch of our lead asset 177Lu-EBTATE and other EB platform technologies,” said Dr. Chris Pak, president and CEO of MTTI, in a statement.
177Lu is designed to precisely destroy tumors when bound to disease-specific, targeting therapeutics and can penetrate soft tissue at a maximum of one millimeter from its binding site. It is covered by the NIH's Evans Blue Platform technology patents. The EB helps boost 177Lu's half-life of 6.7 days and delivers a high dosage to the targeted tumor.
Isotopia uses a unique, stable GMP method to produce a highly pure form of 177Lu. n.c.a. and eliminates cost-intensive clinical waste management.
MTTI plans to sell it through an exclusive NIH worldwide license.
"Our strategy is to be a partner to every leading pharmaceutical company developing Lu-177 n.c.a.-based products, supporting them from clinical trials through commercial sale. We are committed to produce 52 weeks per year, ensuring supply through long-term contracts,” said Isotopia's CEO Dr. Eli Shalom.